Lexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia

December 21, 2022

https://www.globenewswire.com/news-release/2022/12/21/2578251/0/en/Lexicon-Announces-Topline-Results-From-Phase-2-Proof-of-Concept-Study-of-LX9211-in-Postherpetic-Neuralgia.html

LX9211 demonstrated clear evidence of effect, achieving Lexicon’s goal for the study of supporting advancement in another indication within neuropathic pain

Read more at globenewswire.com

Related news for (LXRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.